<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014260</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00001755</org_study_id>
    <nct_id>NCT01014260</nct_id>
  </id_info>
  <brief_title>Doxycycline Outcomes in Lupus Erythematosus</brief_title>
  <official_title>Doxycycline Outcomes in Lupus Erythematosus: (DOLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular disease, specifically from atherosclerosis, is the major cause of mortality in
      SLE in developed countries. In a recent study the investigators have shown that high
      sensitivity C reactive protein (hs-CRP) is higher in SLE patients with (versus without)
      coronary calcium, a measure of subclinical atherosclerosis. In an ongoing two year
      intervention trial of atorvastatin, the investigators will determine if statins retard
      coronary calcium and reduce hs-CRP. However, 10% of the patients in the trial were intolerant
      of statins. The investigators want to now investigate whether there are additional, and
      potentially safer ways, to reduce hs-CRP in SLE. In this study, the investigators will
      determine if doxycycline reduces hs-CRP and other vascular inflammatory markers including
      interleukin 6 (IL-6), soluble vascular cell adhesion molecule (sVCAM-1), soluble inter cell
      adhesion molecule (s-ICAM-1) and matrix metalloproteinase 9 (MMP-9) in SLE.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    We could not get funding for study.
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine whether doxycycline 20 mg bid (periostat) versus 100mg bid versus placebo is more effective in reducing hs-CRP.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxycycline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This is a randomized double-blind clinical trial of doxycycline 20 mg bid versus 100mg bid versus placebo, given for 3 months, to be conducted at a single center (JHH).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Doxycycline 20 mg bid versus Doxycycline 100 mg bid versus placebo</description>
    <arm_group_label>Doxycycline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a clinical diagnosis of SLE, with a hs-CRP above &gt; 3mg/L, (high risk
             level) for the last 3 months, are eligible.

          2. Patients must be 18 years of age or older and able to give informed consent.

          3. Contraception other than OCPs is necessary if a woman is at risk for pregnancy.

        Exclusion Criteria:

          1. SLE patients who are allergic to doxycycline or other tetracyclines.

          2. Patients who are pregnant or are planning to become pregnant.

          3. Patients who are on oral contraceptives (any method of contraception other than OCPs
             can be used.

          4. Tetracycline use within the previous 2 weeks of enrollment.

          5. Patients who are currently on statins will be excluded, because statins might reduce
             hs- CRP.

          6. Patients who are on warfarin.

          7. Patients whose most recent EKG shows significant cardiac dysrhythmias or heart block.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Petri, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University SOM. 1830 East Monument St, Ste 7500</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2009</study_first_submitted>
  <study_first_submitted_qc>November 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2009</study_first_posted>
  <last_update_submitted>March 29, 2012</last_update_submitted>
  <last_update_submitted_qc>March 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2012</last_update_posted>
  <responsible_party>
    <name_title>Michelle Petri</name_title>
    <organization>Johns Hopkins University</organization>
  </responsible_party>
  <keyword>Inflammatory markers of cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

